Loading clinical trials...
Loading clinical trials...
A Phase I, Single Dose, Open-Label Study Comparing the Pharmacokinetics and Safety of Pretomanid in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects
Conditions
Interventions
PA-824
Locations
2
United States
Saint Louis University Center for Vaccine Development
St Louis, Missouri, United States
Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit
Durham, North Carolina, United States
Start Date
March 29, 2018
Primary Completion Date
August 26, 2023
Completion Date
November 17, 2023
Last Updated
June 10, 2025
NCT06192160
NCT05947890
NCT05989802
NCT05941052
NCT06272812
NCT02354014
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions